Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
Moodys
Dow
McKesson
Express Scripts

Last Updated: November 12, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,630,162

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,630,162 protect, and when does it expire?

Patent 6,630,162 protects DETROL LA and is included in one NDA.

Protection for DETROL LA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has one hundred and thirty-seven patent family members in forty-four countries.

Summary for Patent: 6,630,162
Title: Pharmaceutical formulation and its use
Abstract:The invention relates to a pharmaceutical formulation containing tolterodine or a tolterodine-related compound, or a pharmacologically acceptable salt thereof, as active ingredient, in which the formulation exhibits a controlled in vitro release of the active ingredient in phosphate buffer at pH 6.8 of not less than about 80% after 18 hours, and after oral administration to a patient is capable of maintaining a substantially constant serum level of the active moiety or moieties for 24 hours. The invention also relates to the use of the pharmaceutical formulation for treating overactive bladder and gastrointestinal disorders.
Inventor(s): Nilvebrant; Lisbeth (Bromma, SE), Hallen; Bengt (Sollentuna, SE), Olsson; Birgitta (Stenhamra, SE), Strombom; Jan (Vattholm, SE), Gren; Torkek (Kalamazoo, MI), Ringberg; Anders (Stockholm, SE), Wikberg; Martin (Kullavik, SE)
Assignee: Pharmacia AB (Stockholm, SE)
Application Number:09/708,428
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,630,162
Patent Claim Types:
see list of patent claims
Formulation; Compound; Dosage form; Use;

Drugs Protected by US Patent 6,630,162

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Pharmacia And Upjohn DETROL LA tolterodine tartrate CAPSULE, EXTENDED RELEASE;ORAL 021228-001 Dec 22, 2000 AB RX Yes No   Start Trial   Start Trial Y   Start Trial
Pharmacia And Upjohn DETROL LA tolterodine tartrate CAPSULE, EXTENDED RELEASE;ORAL 021228-002 Dec 22, 2000 AB RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,630,162

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden0000782Mar 09, 2000

International Family Members for US Patent 6,630,162

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 1323   Start Trial
African Regional IP Organization (ARIPO) 1529   Start Trial
Argentina 027815   Start Trial
Argentina 029311   Start Trial
Austria 247458   Start Trial
Austria 300941   Start Trial
Austria 405254   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
Baxter
Moodys
Express Scripts
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.